My mother died in my home in hospice in 2020, on the day my state of Washington went into COVID-19 lockdown. Her body was ...

cCFF Therapeutics Development Center, National Jewish Health, Denver, CO, USA dDepartments of Internal Medicine and Pediatrics, Divisions of Pulmonary ... effects in a small number of people with ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

This blog describes a typical ILD patient journey from the initial diagnosis through its long-term management to end-of-life ...

Ioannis Sapountzis, head of global therapeutic areas at Boehringer, said that FIBRONEER-IPF is the largest trial in IPF ...

Living with IPF has brought many emotional ups and downs for columnist Sam Kirton, and recent events have caused him to hit ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.

Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...

Topline data from FIBRONEER-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52 vers ...